Pfizer has selected a preclinical development candidate under its R&D collaboration with TCG Lifesciences Ltd. (TCGLS). Pfizer will own the candidate and other backup candidates and TCGLS will receive a success-based milestone payment.
 
The candidate is a small molecule new chemical entity that has met Pfizer’s criteria, including potency, pharmacokinetics, animal pharmacology, toxicology and related parameters.

Mr. Swapan Bhattacharya, managing director, TCGLS, said, “We have established an excellent track record in our long term collaboration with Pfizer and this candidate nomination is a key milestone of the success of this partnership. This success also demonstrates the progress made by TCGLS in supporting innovation. I sincerely acknowledge the dedication of both the Pfizer and TCGLS scientific teams and congratulate them for this achievement.”